logo

For the Inventor, By the Inventor

Lund, Sweden

Jan Dahmen

This inventor holds 6 USPTO granted patents and 2 EPO patents. Top assignees: Astrazeneca Ab, Bayer Pharma Aktiengesellschaft, Bayer Schering Pharma Ag. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Dahmen. Retrieved from https://idiyas.com/inventor/jan-dahmen-o6043ihu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

 

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 19(Granted Patents)


Location History:

  • Akarp, SE (2011 - 2013)
  • Lund, SE (2011 - 2017)

Company Filing History:

goldMedal4 out of 1,534 
 
Astrazeneca Ab
 patents
silverMedal4 out of 387 
 
Bayer Pharma Aktiengesellschaft
 patents
bronzeMedal2 out of 192 
 
Bayer Schering Pharma Ag
 patents
where one patent can have more than one assignee

Years Active: 2011-2017

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 9738632 - Phenyl and benzodioxinyl substituted indazoles derivatives (2017-08-22),
2. 9512110 - Phenyl and benzodioxinyl substituted indazoles derivatives (2016-12-06),
3. 8461346 - Benzyl amines, a process for their production and their use as anti-inflammatory agents (2013-06-11),
4. 8173676 - Benzyl, amines, a process for their production and their use as anti-inflammatory agents (2012-05-08),
5. 8030340 - Indazolyl sulphonamide derivatives useful as glucocorticoid modulators (2011-10-04),
6. 7999108 - Benzyl amines, a process for their production and their use as anti-inflammatory agents (2011-08-16),

Title: Jan Dahmen: Innovator in Pharmaceutical Chemistry

Introduction

Jan Dahmen is a prominent inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 6 patents. His work focuses on novel compounds that have potential applications in medicine.

Latest Patents

Among his latest patents, Jan Dahmen has developed phenyl and benzodioxinyl substituted indazoles derivatives. These compounds are described by a specific formula and relate to novel indazolyl derivatives. The present invention encompasses pharmaceutical compositions that include these derivatives, processes for their preparation, and their use as medicaments.

Career Highlights

Throughout his career, Jan Dahmen has worked with notable companies in the pharmaceutical industry, including AstraZeneca AB and Bayer Pharma Aktiengesellschaft. His experience in these organizations has allowed him to advance his research and contribute to innovative solutions in healthcare.

Collaborations

Jan has collaborated with esteemed colleagues such as Markus Berger and Hartmut Rehwinkel. These partnerships have fostered a collaborative environment that enhances the development of new pharmaceutical compounds.

Conclusion

Jan Dahmen's work exemplifies the impact of innovation in pharmaceutical chemistry. His patents and collaborations reflect a commitment to advancing medical science through novel compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…